IL117773A - Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability - Google Patents

Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability

Info

Publication number
IL117773A
IL117773A IL11777396A IL11777396A IL117773A IL 117773 A IL117773 A IL 117773A IL 11777396 A IL11777396 A IL 11777396A IL 11777396 A IL11777396 A IL 11777396A IL 117773 A IL117773 A IL 117773A
Authority
IL
Israel
Prior art keywords
oral bioavailability
coenzyme
enhanced oral
lipid compositions
solid lipid
Prior art date
Application number
IL11777396A
Other languages
English (en)
Other versions
IL117773A0 (en
Inventor
Shimon Amselem
Original Assignee
Pharmos Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Ltd filed Critical Pharmos Ltd
Priority to IL11777396A priority Critical patent/IL117773A/xx
Publication of IL117773A0 publication Critical patent/IL117773A0/xx
Priority to CA002251194A priority patent/CA2251194C/en
Priority to AT97920049T priority patent/ATE301454T1/de
Priority to EP97920049A priority patent/EP0954284B1/en
Priority to PCT/US1997/005453 priority patent/WO1997036577A1/en
Priority to JP53557397A priority patent/JP4219403B2/ja
Priority to IL12638497A priority patent/IL126384A/en
Priority to ES97920049T priority patent/ES2249797T3/es
Priority to AU24339/97A priority patent/AU722217B2/en
Priority to BR9708423-9A priority patent/BR9708423A/pt
Priority to DE69733966T priority patent/DE69733966T2/de
Priority to US08/833,075 priority patent/US5989583A/en
Publication of IL117773A publication Critical patent/IL117773A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
IL11777396A 1996-04-02 1996-04-02 Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability IL117773A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL11777396A IL117773A (en) 1996-04-02 1996-04-02 Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US08/833,075 US5989583A (en) 1996-04-02 1997-04-02 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
PCT/US1997/005453 WO1997036577A1 (en) 1996-04-02 1997-04-02 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
AT97920049T ATE301454T1 (de) 1996-04-02 1997-04-02 Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit
EP97920049A EP0954284B1 (en) 1996-04-02 1997-04-02 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
CA002251194A CA2251194C (en) 1996-04-02 1997-04-02 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
JP53557397A JP4219403B2 (ja) 1996-04-02 1997-04-02 経口の生物学的利用率増大のための親油性化合物の固形脂質組成物
IL12638497A IL126384A (en) 1996-04-02 1997-04-02 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
ES97920049T ES2249797T3 (es) 1996-04-02 1997-04-02 Composiciones de lipidos solidos de componentes lipofilicos para mejorar la biodisponibilidad oral.
AU24339/97A AU722217B2 (en) 1996-04-02 1997-04-02 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
BR9708423-9A BR9708423A (pt) 1996-04-02 1997-04-02 Composição lipìdica sólida seca, e, processos para produzir a mesma e para liberar uma substância lipofìlica em um mamìfero em necessidade de tal substância.
DE69733966T DE69733966T2 (de) 1996-04-02 1997-04-02 Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11777396A IL117773A (en) 1996-04-02 1996-04-02 Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability

Publications (2)

Publication Number Publication Date
IL117773A0 IL117773A0 (en) 1996-08-04
IL117773A true IL117773A (en) 2000-10-31

Family

ID=11068733

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11777396A IL117773A (en) 1996-04-02 1996-04-02 Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability

Country Status (10)

Country Link
US (1) US5989583A (show.php)
EP (1) EP0954284B1 (show.php)
JP (1) JP4219403B2 (show.php)
AT (1) ATE301454T1 (show.php)
AU (1) AU722217B2 (show.php)
BR (1) BR9708423A (show.php)
DE (1) DE69733966T2 (show.php)
ES (1) ES2249797T3 (show.php)
IL (1) IL117773A (show.php)
WO (1) WO1997036577A1 (show.php)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726343D0 (en) * 1997-12-13 1998-02-11 Auffret Anthony The use of excipients to accelerate freeze-drying
CN1306438A (zh) * 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
WO2000040219A1 (en) 1998-12-30 2000-07-13 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosporin
US6242491B1 (en) * 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
AU2001257359A1 (en) 2000-04-27 2001-11-07 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
AU2001279284A1 (en) * 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
DE10035513A1 (de) * 2000-07-21 2002-01-31 Beiersdorf Ag Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen
WO2002026372A2 (en) 2000-09-27 2002-04-04 Verion Inc. Instant water dissolvable encapsulate and process
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
AU1608502A (en) * 2000-12-14 2002-06-24 Hoffmann La Roche Self emulsifying lipid matrix (selm)
EP1343372A2 (en) 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6806069B2 (en) * 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
US6864231B2 (en) * 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
DK1249230T3 (da) * 2001-04-12 2004-03-15 Vesifact Ag Mikroemulsion-prækoncentrater og mikroemulsioner indeholdende coenzym Q10
WO2003000236A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20040015519A1 (en) * 2001-10-15 2004-01-22 Yukitoshi Maeda Content delivery server and content delivery system having the same
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
TW200302054A (en) * 2002-01-18 2003-08-01 Kaneka Corp Ubiquinone-enriched foods
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
HRP20040816A2 (en) * 2002-04-03 2005-06-30 Solvay Pharmaceuticals B.V. Stabilized natural cannabinoid formulation
AR039194A1 (es) 2002-04-03 2005-02-09 Solvay Pharm Bv Formulacion de cannabinoides naturales estabilizados
US20060093661A1 (en) * 2002-05-07 2006-05-04 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
RU2005103625A (ru) 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) Фармацевтические композиции полуупорядоченных лекарств и полимеров
CA2480668C (en) 2002-08-19 2009-11-24 Art Jen Complexus, Inc. Compositions comprising dietary fat complexer and methods for their use
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
CA2414763A1 (en) * 2002-12-19 2004-06-19 Aquanova German Solubilisate Technologies (Agt) Gmbh Tocopherol concentrates and method for producing same
US20130085146A1 (en) * 2003-01-14 2013-04-04 Rodney J.Y. Ho Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
JP2004323444A (ja) * 2003-04-25 2004-11-18 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai 凍結乾燥微粒子製剤およびその製法
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
AU2005211936B2 (en) * 2004-02-17 2011-06-09 Markus Graf V. Matuschka-Greiffenclau Alcohol metabolism moderating composition
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
CN101132781A (zh) 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
JP4877899B2 (ja) * 2005-01-25 2012-02-15 学校法人近畿大学 薬物徐放出性球状微粒子及びその製造方法
CA2604952A1 (en) * 2005-04-14 2006-10-19 Jarrow Formulas, Inc. Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration
US8252326B2 (en) 2005-06-01 2012-08-28 Catalent Australia Pty Ltd. Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
WO2007014392A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Benzoquinones of enhanced bioavailability
US20070026073A1 (en) * 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
PL1909600T3 (pl) 2005-07-29 2012-09-28 Tima Found Kompozycja spowalniająca metabolizm alkoholu i ograniczająca ryzyko chorób wywołanych alkoholem
WO2007076454A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
WO2007131047A2 (en) * 2006-05-02 2007-11-15 University Of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
US20070264312A1 (en) * 2006-05-12 2007-11-15 Skaggs Crawford B Rheologically Modified Edible Oils
JP5140585B2 (ja) 2006-06-22 2013-02-06 株式会社カネカ 還元型補酵素ｑ１０含有組成物およびその製造方法
EP2046290A4 (en) * 2006-08-04 2011-08-17 Insys Therapeutics Inc AQUEOUS DRONABINOL FORMULATIONS
ATE516796T1 (de) * 2006-09-15 2011-08-15 Echo Pharmaceuticals Bv Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
JP2010503664A (ja) 2006-09-15 2010-02-04 エコ・ファーマシューティカルズ・ビー．ブイ． 水不溶性医薬活性物質の舌下、頬若しくは経口投与のための医薬投薬単位
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
EP1952803A1 (en) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
CN101622302B (zh) 2007-01-26 2013-01-23 Isp投资公司 生产喷雾干燥产品的制剂工艺方法
US20100092560A1 (en) * 2007-04-16 2010-04-15 Kaneka Corporation Reduced coenzyme q10-containing particulate composition and method for producing the same
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
US9861656B2 (en) * 2007-08-08 2018-01-09 Allergy Research Group, Llc Phospholipid compositions and use thereof to enhance spermatozoa motility and viability
FR2929512B1 (fr) * 2008-04-08 2010-12-31 Roquette Freres Composition pulverulente de maltitol cristallise de grande fluidite et non mottante
WO2010022364A1 (en) * 2008-08-22 2010-02-25 Ackley Donald E Water soluble drugs and supplements
GB0909154D0 (en) * 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010143199A1 (en) * 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US11202831B2 (en) * 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) * 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012129072A1 (en) 2011-03-18 2012-09-27 Particle Dynamics International, Llc Solid particulate compositions comprising coenzyme q10
US10421943B2 (en) * 2011-08-11 2019-09-24 Allergy Research Group, Llc Phospholipid compositions and use thereof to enhance spermatozoa motility, viability and resistance to oxydative damage
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
DE102013004263A1 (de) * 2013-03-13 2014-09-18 Martin Lipsdorf Schnell lösliche orale Darreichungsform und Methode zur Herstellung derselben
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016191651A1 (en) 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
EP3103440A1 (en) 2015-06-12 2016-12-14 INDENA S.p.A. Solid dispersions of coenzyme q10
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
AU2016324349A1 (en) * 2015-09-17 2018-02-15 Pharmako Biotechnologies Pty Limited Ubiquinone and ubiquinol compositions, and methods relating thereto
RU2605616C1 (ru) * 2015-11-27 2016-12-27 Закрытое акционерное общество "Институт экспериментальной фармакологии" Липосомальное средство на основе убихинола и способ его получения
IL259246B2 (en) 2015-12-07 2024-11-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Compositions for oral administration comprising at least one cannabinoid, a method for the preparation thereof and use of same
WO2017100062A1 (en) * 2015-12-09 2017-06-15 Poviva Tea, Llc Methods for formulating orally ingestible compositions comprising lipophilic active agents
MA45279A (fr) * 2016-03-02 2019-01-09 Pathway Intermediates Ltd Aliments pour animaux contenant des glycolipides spécifiques
US20220079881A1 (en) * 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
US11166912B2 (en) * 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
BE1024442B1 (nl) * 2016-07-27 2018-02-28 Nutrisan Nv Samenstelling en gebruik van een voedingssupplement
WO2018035027A1 (en) * 2016-08-15 2018-02-22 Corr-Jensen Inc. TIME RELEASE OF CoQ10
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
IL270682B2 (en) 2017-05-17 2025-09-01 Berg Llc Use of coenzyme q10 formulations for the treatment and prevention of bullous dermatitis of the skin
JP2020528898A (ja) 2017-07-27 2020-10-01 ローカス アイピー カンパニー、エルエルシー 医薬品、サプリメント及び摂取物質のバイオアベイラビリティを増進する組成物
CA3096580C (en) * 2018-04-16 2023-05-23 Poviva Corp. Compositions infused with nicotine compounds and methods of use thereof
CN108379236B (zh) * 2018-04-20 2020-02-18 武汉百纳礼康生物制药有限公司 一种非那雄胺缓释片及其制备方法
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
SG11202106144VA (en) 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US20220257772A1 (en) * 2019-07-19 2022-08-18 Spi Pharma, Inc. Preparation of lipophilic active ingredients
JP2022543695A (ja) * 2019-08-10 2022-10-13 ローカス アイピー カンパニー、エルエルシー Ｏｔｃ及び医薬品のバイオアベイラビリティを増加する方法
EP4013429A4 (en) * 2019-08-14 2023-08-16 Locus IP Company, LLC DRINK SUPPLEMENT COMPOSITION TO IMPROVE HEALTH AND HYDRATION
US20210330683A1 (en) 2020-04-20 2021-10-28 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents
EP3919046A1 (en) 2020-06-02 2021-12-08 Athenion AG Method for solubilizing natural, endogenous and synthetic cannabinoids
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
IT8219012A0 (it) * 1982-01-06 1982-01-06 Ausonia Farma Srl Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
IT1191608B (it) * 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5480865A (en) * 1994-02-25 1996-01-02 Parkinson's Charitable Trust Nutritional composition

Also Published As

Publication number Publication date
ATE301454T1 (de) 2005-08-15
BR9708423A (pt) 2000-01-04
JP4219403B2 (ja) 2009-02-04
DE69733966D1 (de) 2005-09-15
WO1997036577A1 (en) 1997-10-09
EP0954284B1 (en) 2005-08-10
US5989583A (en) 1999-11-23
ES2249797T3 (es) 2006-04-01
EP0954284A4 (en) 2000-01-26
AU722217B2 (en) 2000-07-27
EP0954284A1 (en) 1999-11-10
JP2000507594A (ja) 2000-06-20
DE69733966T2 (de) 2006-05-18
AU2433997A (en) 1997-10-22
IL117773A0 (en) 1996-08-04

Similar Documents

Publication Publication Date Title
IL117773A (en) Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US6312703B1 (en) Compressed lecithin preparations
US8932584B2 (en) Solubilized CoQ-10
CA2063791C (en) Hard gelatine capsule containing fat-soluble nutrients.
CA2264718A1 (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
JPS62501908A (ja) 薬理的組成物及びそれを含有する薬理的製剤
JPS5777626A (en) Palatable composition containing oil or oily substance
HUP0002486A1 (hu) Lipofil vegyületeket tartalmazó ön-emulgeáló készítmény
EP0919225A3 (en) Lipid mix for lip product
WO1998058629A3 (en) Preparation of pharmaceutical compositions
WO2002043659A3 (en) Composition containing statins and calcium for improved cardiovascular health
AU1347899A (en) Conjugated linoleic acid delivery system in cosmetic preparations
JP5286086B2 (ja) 還元型補酵素ｑ１０及びリゾレシチンを含有する組成物
MY111841A (en) Injectable liposomal pharmaceutical preparations
ES2162586A1 (es) Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
ES2149979T3 (es) Composicion estabilizada para la administracion oral de peptidos.
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
EP1670325A1 (en) SOLUBILIZED CoQ-10
DE60019239D1 (de) Fettlösliche Vitamine enthaltende Zusammensetzungen
ES2174054T3 (es) Composiciones farmaceuticas acuosas liquidas que comprenden alginato sodico y bicarbonato potasico.
DK0973515T3 (da) Faste sammensætninger, der er egnet til oral indgivelse, hvilke sammensætninger omfatter et alkanoyl-L-carnitinmagnesiumcitrat
EP2668939A1 (en) Composition containing polyunsaturated fatty acid
WO2003028624A3 (en) Levothyroxine compositions and methods
CA2251194A1 (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
WO2003013441A3 (en) Levothyroxine compositions and methods

Legal Events

Date Code Title Description
FF Patent granted
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired